📰 Beigene News
Page 8 - Beigene News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.
June 28, 2023
BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) insider Lai Wang sold 1,108 shares of the business’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $181.92, for a total value of $201,567.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can […]
June 16, 2023
BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) major shareholder Advisors Ltd. Hhlr sold 273,728 shares of the firm’s stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $207.72, for a total transaction of $56,858,780.16. Following the completion of the sale, the insider now directly owns 142,888,241 shares of […]
June 16, 2023
BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) major shareholder Advisors Ltd. Hhlr sold 273,728 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $207.72, for a total transaction of $56,858,780.16. Following the sale, the insider now owns 142,888,241 shares in the company, […]
June 16, 2023
The law firm of Kirby McInerney LLP is investigating potential claims against BeiGene Ltd. . The investigation concerns whether BeiGene and/or certain of its officers have violated the federal... | June 16, 2023
June 15, 2023
BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics patent issued on June 13, 2023. Pharmacyclics is an AbbVie Inc (NYSE: ABBV) company. As per a Bloomberg Law report, AbbVie filed a lawsuit against the China-based company alleging a patent violation related to Brukinsa. "BeiGene's work is original, and we will vigorously defend against all allegation...
June 15, 2023
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BeiGene, Ltd. resulting from allegations that BeiGene... | June 15, 2023
June 12, 2023
BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) COO Xiaobin Wu sold 3,291 shares of the firm’s stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $224.73, for a total transaction of $739,586.43. The sale was disclosed in a legal filing with the SEC, which can be […]
June 6, 2023
BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) has received an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokerages that […]
June 6, 2023
BeiGene, Ltd. (NASDAQ:BGNE – Get Rating)’s stock price traded down 3.1% on Tuesday . The stock traded as low as $212.34 and last traded at $215.03. 16,488 shares were traded during mid-day trading, a decline of 92% from the average session volume of 212,068 shares. The stock had previously closed at $221.84. Analyst Ratings Changes […]
May 30, 2023
BeiGene's BTKi is approved in more than 65 markets globally BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a